相关实验视频

Updated: Jun 15, 2026

Investigating the Phagocytosis of Leishmania using Confocal Microscopy
08:41

Investigating the Phagocytosis of Leishmania using Confocal Microscopy

Published on: July 29, 2021

3.8K

葡萄甘是一种有前途的异化增强剂,可诱导巨细胞细胞分裂

Bernadette Dian Novita1, Widya Wasiyastuti2, Yudy Tjahjono3

  • 1Department of Pharmacology and Therapy, Faculty of Medicine, Widya Mandala Surabaya Catholic University, Surabaya, Indonesia.

Journal of advanced pharmaceutical technology & research
|September 18, 2024
PubMed
概括

葡萄甘增强了巨细胞的活性,并增强了对抗耐药结核病的异化的疗效. 这项研究表明,葡萄甘可以改善 fagocytosis 在不影响 isoniazid 的情况下.

关键词:
特性概况 特性概况结核病菌菌菌的结核病菌的结核病菌.葡萄康曼南 (Glucomannan) 是一种葡萄素.异化是一种异化.巨细胞的 fagocytosis 的发生.

更多相关视频

Phagosome Migration and Velocity Measured in Live Primary Human Macrophages Infected with HIV-107:32

Phagosome Migration and Velocity Measured in Live Primary Human Macrophages Infected with HIV-1

Published on: September 5, 2016

8.2K
High Throughput Fluorometric Technique for Assessment of Macrophage Phagocytosis and Actin Polymerization09:22

High Throughput Fluorometric Technique for Assessment of Macrophage Phagocytosis and Actin Polymerization

Published on: November 27, 2014

14.7K

相关概念视频

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...